Key result
Arterial stiffness measured by brachial oscillometry in community pharmacies will be evaluated for its predictive value for incident hypertension and cardiovascular disease in the upcoming COPHARTEN observational study.
Why the study?
Arterial stiffness has prognostic value for cardiovascular diseases and may cause hypertension, but its impact on SCORE risk calculation, prediction of incident hypertension, and association with hypertension control needed evaluation.
Does measurement of arterial stiffness in community pharmacies improve cardiovascular risk stratification and predict incident hypertension in normotensive and hypertensive patients?
Observational (n=2,400)
Yes
Does measurement of arterial stiffness in community pharmacies improve cardiovascular risk stratification and predict incident hypertension in normotensive and hypertensive patients?
This study protocol describes a prospective observational trial to evaluate the utility of arterial stiffness measurement in community pharmacies for cardiovascular risk stratification and predicting incident hypertension.
Answers are grounded in this paper and cite their sources.
May refine SCORE-based CV risk assessment and flag normotensives for incident HTN; leaves open prospective validation before clinical adoption.
Background and Objective Arterial Stiffness (AS) measured as pulse wave velocity has emerged in recent years as a hypertension mediated organ damage with independent prognostic value for Cardiovascular (CV) diseases that has also been discussed as a potential cause of Hypertension (HTN). The aim of this study is to (1) evaluate how measurement of AS modifies CV risk calculation by SCORE, (2) to measure the predictive value of AS for incident hypertension in normotensive patients, and (3) to analyze the association between control of HTN and presence of AS in sustained HTN. Patients and Methods A longitudinal, prospective, observational trial under conditions of daily pharmaceutical and clinical practice will be conducted in approximately 60 community pharmacies of the Iberian Peninsula in normotensive and/or hypertensive patients entering a pharmacy spontaneously. In the first cross-sectional step, AS will be estimated with a semiautomatic, validated device (Mobil-O-Graph ® , IEM), followed by a 10-item questionnaire. The patients will be referred to Primary Care for stratifying risk by SCORE tables and standard evaluation. In the second longitudinal step, patients will be asked to repeat the visit after 12 months. Discussion This study aims to improve CV risk stratification and to investigate the potential of AS in predicting incident HTN in normotensive subjects. Besides, it will analyze the role of arterial stiffness as an associated factor to prevent control in sustained HTN in a setting of cooperation between community pharmacies and physicians in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Rodilla et al. (2019) conducted an observational in Hypertension (n=2,400). Elevated arterial stiffness (pulse wave velocity) vs. Normal arterial stiffness was evaluated on Difference in the rate of incident hypertension and development of major adverse cardiac events (MACE). Arterial stiffness measured by brachial oscillometry in community pharmacies will be evaluated for its predictive value for incident hypertension and cardiovascular disease in the upcoming COPHARTEN observational study.
Synapse has enriched 10 related papers. Consider them for comparative context: